July 18, 2016 **Financial Technology Partners**

FT Partners Research – Transaction Profile



acquires



for

\$145 million

Courtesy of:



The Only Investment Bank Focused Exclusively on Financial Technology

www.ftpartners.com



Financial Technology Partners

555 Mission St., 23rd Floor San Francisco, CA 94105 Tel: 415.512.8700 Steve McLaughlin

Managing Partner

Tel: 415.992.8880

steve.mclaughlin@ftpartners.com



Transaction Overview

Transaction Summary

- On July 18, 2016, Evolent Health entered a definitive agreement to acquire the majority of Valence health's business for approx. \$145 mm in cash and stock
 - The transaction also includes an earn-out of up to \$50 mm, payable in stock, tied to future new business activity
- Under the terms of the agreement, Evolent will acquire the majority of Valence Health's business, excluding its contracts serving state insurance cooperatives
 - The state insurance cooperative contracts will be transferred to a separate entity that will maintain operations as they currently exist today, which will be owned by Valence shareholders
- Together, the organizations will be able to serve more than 1.8 mm lives across 23 long-term operating partners at closing, comprised of provider-sponsored health plans, accountable care organizations and fullrisk entities
- Evolent expects the acquired business, on a standalone basis, to generate revenues of approximately \$80-85 mm for 2016
 - Evolent will consolidate the results of the acquired business only for the period subsequent to the close of the transaction
- The companies expect the transaction to close within the next 120 days, subject to regulatory approvals and certain closing conditions set forth in the agreement

Transaction Commentary

"By adding Valence Health's services to Evolent, we expect to strengthen our operational capabilities and expertise, expanding our ability to support provider organizations in delivering higher quality, lower cost care. Strategically, we have tightly aligned visions of improving health care through innovative technology and services that help providers succeed as the industry continues its adoption of value-based payment models. Practically, we expect the addition of Valence Health's talented team and their experience in value-based administration will advance our ability to drive results for a broader set of clients, providers and patients. We are looking forward to welcoming Valence Health employees and clients to the Evolent team."



Frank Williams

"Our two organizations are culturally and operationally aligned to deliver robust value-based administration and services to health care providers. Combining our team's 20 years of clinical and strategic experience with Evolent's proven innovations in value-based care will allow us to better serve our clients with best-inclass technology, clinical models and administrative service capabilities."

Valence Health



Andrew Eckert CEO





Valence Health Overview

Valence Health Overview

Headquarters:Chicago, ILFounded:1996Employees:503

- Valence health is a provider of clinical integration and data management software
- The Company's clinical integration solution includes assistance with physician integration strategies, data collection and analysis, performance reporting and pointof-care tools
- The Company provides outsourced administrative management services to health plans and clinical integration solutions through data analytics and other custom tools to support provider organizations


Recent Financing Transactions

Date	Size (\$ mm)	Investor(s)	
11/19/14 \$15		HERITAGE GROUP PARTNERS IN HEALTHCARE GE VENTURES NORTH BRIDGE growth equity venture partners	
06/19/12	30	North Bridge	

venture bartners

Product Overview

Valence Health offers all the necessary technology, analytics, expertise, and managed services to power provider organizations' value-based transformation



Software Solution and Service Offerings

- ✓ Value-Based Consulting
- ✓ Data Collection
- ✓ Vision Platform
- vElect for IPAs contract administration
- Quality Measurement
- ✓ Value-Based Managed Services
- ✓ Cost & Utilization
- ✓ Actuarial Services





Evolent Health Overview




CEO Frank Williams
Headquarters: Nashville, TN
Founded: 1995
Employees: 5,001

Evolent Health provides an end-to-end technologyenabled services platform helping healthcare providers transition to value based payment models

Selected Transactions						
Date	Size (\$ mm)	Туре	Target / Investor			
			Investor(s):			
07/04/15	\$196	IPO	Public			
09/30/13	100	Series B Financing	Investor(s): The Advisory OXEON Company UPMC HEALTH PLAN			
			Investor(s):			
05/07/12	25	Seed Financing	Undisclosed Investor(s)			

Evolent Health (NYSE: EVH) LTM Stock Chart



Key Financial Statistics (LTM as of 12/31/15)

Total Revenue (mil.)	\$96.9
Growth Over Prior Year	NA
Gross Profit (mil.)	\$39.5
Margin %	40.8%
EBITDA (mil.)	(\$31.5)
Margin %	(32.5%)
Net Income (mil.)	\$332.5
Margin %	343.2%
Diluted EPS Excl. Extra Items	\$6.93





Evolent Health Overview

Founders







Evolent Overview

Value-Based Operations <u>Step 1</u> Blueprint → Step 2 & Identifi®

- Founded in 2011, the Company was developed by UPMC & The Advisory Board
 - UPMC operates the nation's largest provider-owned health plan behind Kaiser Permanente
 - The Advisory Board provides best practice research and technology solutions to over 3,900 hospitals and providers
- Focused on large long-term customer contracts with health care providers and health systems
 - To date. Evolent Health has secured ten long-term. contracts worth \$700 mm in future total contract value
 - Expects to continue to grow as the Companies' partners increase membership in existing value-based programs, through expanding product offering and acquiring new partners
- Every long-term partnership begins with a system transformation process called "Blueprint"
 - Evolent Health works with the healthcare provider's Board of Directors and senior management
 - A significant portion of providers that go through the Blueprint process continue to partner with the Company for its proprietary processes and services known as Value-Based Operations
- Value-Based models include Direct to Employer, Payer Contracts & Provider Owned Health Plans





Financial and Administrative Management

Integrated Specialty

Partnerships





Quality and Risk Coding





FT Partners is the Leader in Financial Technology Investment Banking


FT Partners has advised on some of the most prominent transactions in the Healthcare and Insurance IT sectors

























FT Partners Advises on \$80,000,000 Sale of Benaissance

Transaction Overview and Rationale

Overview of Transaction

- On October 15, 2015, Benaissance, LLC ("Benaissance" or the "Company") announced it has entered into a definitive agreement to be acquired by WEX for \$80mm
- Headquartered in Omaha, NE, Benaissance is a leading provider of integrated Software-as-a-Service (SaaS) technologies and services for healthcare premium billing, payment and workflow management
 - Existing investors include Omaha-based, McCarthy Capital
- WEX is a leading, multi-channel provider of corporate payment solutions representing more than 9 million vehicles and serving a wide variety of business sectors
- The transaction is expected to close in the fourth quarter of 2015 and is subject to applicable regulatory approvals and other customary closing conditions

Significance of Transaction

- Represents a highly-attractive outcome for both Benaissance and WEX
- Combined resources and expertise of Benaissance and WEX position the Company extraordinarily well to further its leadership in the marketplace
- Enables WEX to provide an expanded and differentiated payments solution in order to grow its addressable market opportunity and wallet share in the healthcare market
- Benaissance will be integrated with WEX's existing Evolution1 platform creating an opportunity for potential synergies as the businesses already share a number of mutual partners and customers

FT Partners' Role

- FT Partners served as exclusive strategic and financial advisor to Benaissance and its Board of Directors
- Transaction highlights FT Partners' continued success advising leading companies and generating highly successful outcomes in the Healthcare / Benefits IT and Services space

FINANCIAI Technology Partners LP FTP Securities LLC

is pleased to announce its exclusive role as sole strategic and financial advisor to



in its sale to



for a total consideration of

\$80,000,000



The Only Investment Bank
Focused Exclusively on Financial Technology
www.ftpartners.com



Selected FT Partners' Research (click to view)



Wipro Acquires HealthPlan Services for \$460 million



IBM Watson Health Acquires
Truven Health Analytics for
\$2.6 billion



Maestro Health Raises \$53 million in Financing



New Mountain Capital Acquires Equian for \$225 million



Bright Health Raises \$80 million in Series A Financing



Pamplona Acquires MedAssets for \$2.7 billion



Insureon Raises \$31 million in Series B Led by Oak HC/FT



Benaissance's Sale to WEX for \$80 million



FT Partners regularly publishes research highlighting the most important transactions, trends and insights impacting the global Financial Technology landscape. Our unique insight into FinTech is a direct result of executing hundreds of transactions in the sector combined with over 13 years of exclusive focus on Financial Technology. Please visit our <u>subscription form</u> to subscribe to our exclusive monthly newsletter and receive our research reports.


Award-Winning Investment Banking Franchise Focused on Superior Client Results

FT Partners has been recognized as Investment Banking Firm of the Year and regularly achieves Merger and Financing Deal of the Year recognition

	2016	 Investment Banking Firm of the Year Cross Border Deal of the Year 	
	2015	■ Dealmaker of the Year ■ Technology Deal of the Year	
2016 - 2004	2014	■ Equity Financing Deal of the Year ■ Professional Services Deal of the Year, Above \$100mm	
ANNUAL AWARDS	2012	 Dealmaker of the Year Professional Services Deal of the Year, Above \$100mm 	
WINNER M&A Advisor	2011	 Boutique Investment Bank of the Year Deal of the Decade 10 Deal of the Year Nominations Across 9 Categories 	
Awards	2010	■ Upper Middle Market Deal of the Year, Above \$500 mm ■ IT Services Deal of the Year, Below \$500mm ■ Cross-Border Deal of the Year, Below \$500mm	
	2007	 Dealmaker of the Year - Steve McLaughlin Business to Business Services Deal of the Year Computer and Information Technology Deal of the Year, Above \$100mm Financial Services Deal of the Year, Above \$100mm 	
Institutional	2015	■ Steve McLaughlin ranked #4 in Institutional Investor's FinTech 35 List	
Institutional Investor Annual Ranking	2006-2008	■ Consecutively ranked (2006, 2007 and 2008) among the top Bankers in Financial Technology	
WINNER	2008	 Equity Financing Dealmaker of the Year – Steve McLaughlin Information Technology Deal of the Year Financial Services Deal of the Year 	
Middle Market Financing Awards	2006	 Financing Professional of the Year – Steve McLaughlin Financing Deal of the Year - Equity Financing Deal of the Year - Debt 	- 9



Platform of Choice for Clients and Bankers Alike





The FT Partners Senior Banking Team

Name / Position	Prior Background	Experience / Education	Years of Experience
Steve McLaughlin Founder, CEO and Managing Partner	Goldman Sachs	 Formerly with Goldman, Sachs & Co. in New York and San Francisco from 1995-2002 Formerly Co-Head of Goldman Sachs' Financial Technology Group (#1 market share) Wharton M.B.A. 	21
Larry Furlong Managing Director	Goldman Sachs	 Formerly with Goldman, Sachs & Co. in New York, London and Los Angeles beginning in 1995 Wharton M.B.A. 	21
Greg Smith Managing Director	Merrill Lynch J.P.Morgan	 Formerly award winning Equity Research Analyst at Merrill Lynch / J.P. Morgan / Sterne Agee Recent coverage included WU, EEFT, DST, ENV, FISV, FIS, V, MA, GPN & HPY among others 	20
Steve Stout Managing Director	J.P.Morgan	Formerly with J.P. Morgan and UBSFormerly Global Head of Strategy at First Data	18
Tim Wolfe Managing Director	Goldman Sachs	 Formerly with Goldman, Sachs & Co. beginning in 2000 Started at FT Partners in 2002 40 Under 40 M&A Advisor Award Winner 2013 Harvard M.B.A. 	14
Andrew McLaughlin Managing Director, Research & Business Development	Deloitte.	 Leads FT Partners' Research and Business Development Team Formerly with Deloitte Consulting 	10

